FDA Grants Fast Track to Coramitug for ATTR-CM, Supporting Amyloid-Clearing Phase 3 Trial

The FDA granted Fast Track Designation to coramitug, an investigational anti-TTR antibody designed to clear existing amyloid deposits in ATTR cardiomyopathy.

The US Food and Drug Administration (FDA) has granted Fast Track Designation to coramitug (PRX004) for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM).1